In summary, with the limitation of a relatively small sample size in this pivotal study, our data suggest that an early increase in HMGB1 levels in response to the first cycle of neoadjuvant chemotherapy may correlate with improved long‐term outcome in early stage breast cancer patients receiving neoadjuvant chemotherapy. Here, HMGB1 is linked to breast carcinoma.